279 related articles for article (PubMed ID: 12097269)
1. Raloxifene, a selective estrogen receptor modulator, induces apoptosis in androgen-responsive human prostate cancer cell line LNCaP through an androgen-independent pathway.
Kim IY; Seong DH; Kim BC; Lee DK; Remaley AT; Leach F; Morton RA; Kim SJ
Cancer Res; 2002 Jul; 62(13):3649-53. PubMed ID: 12097269
[TBL] [Abstract][Full Text] [Related]
2. Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines.
Kim IY; Kim BC; Seong DH; Lee DK; Seo JM; Hong YJ; Kim HT; Morton RA; Kim SJ
Cancer Res; 2002 Sep; 62(18):5365-9. PubMed ID: 12235008
[TBL] [Abstract][Full Text] [Related]
3. Interruption of nuclear factor kappaB signaling by the androgen receptor facilitates 12-O-tetradecanoylphorbolacetate-induced apoptosis in androgen-sensitive prostate cancer LNCaP cells.
Altuwaijri S; Lin HK; Chuang KH; Lin WJ; Yeh S; Hanchett LA; Rahman MM; Kang HY; Tsai MY; Zhang Y; Yang L; Chang C
Cancer Res; 2003 Nov; 63(21):7106-12. PubMed ID: 14612503
[TBL] [Abstract][Full Text] [Related]
4. Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptor α and β.
Rossi V; Bellastella G; De Rosa C; Abbondanza C; Visconti D; Maione L; Chieffi P; Della Ragione F; Prezioso D; De Bellis A; Bellastella A; Sinisi AA
J Cell Physiol; 2011 May; 226(5):1334-9. PubMed ID: 20945400
[TBL] [Abstract][Full Text] [Related]
5. A novel dietary triterpene Lupeol induces fas-mediated apoptotic death of androgen-sensitive prostate cancer cells and inhibits tumor growth in a xenograft model.
Saleem M; Kweon MH; Yun JM; Adhami VM; Khan N; Syed DN; Mukhtar H
Cancer Res; 2005 Dec; 65(23):11203-13. PubMed ID: 16322271
[TBL] [Abstract][Full Text] [Related]
6. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptor-dependent and -independent mechanisms mediate Ganoderma lucidum activities in LNCaP prostate cancer cells.
Zaidman BZ; Wasser SP; Nevo E; Mahajna J
Int J Oncol; 2007 Oct; 31(4):959-67. PubMed ID: 17786330
[TBL] [Abstract][Full Text] [Related]
8. C-Jun N-terminal kinase is required for phorbol ester- and thapsigargin-induced apoptosis in the androgen responsive prostate cancer cell line LNCaP.
Engedal N; Korkmaz CG; Saatcioglu F
Oncogene; 2002 Feb; 21(7):1017-27. PubMed ID: 11850819
[TBL] [Abstract][Full Text] [Related]
9. Apoptosis of human prostate androgen-dependent and -independent carcinoma cells induced by an isopropanolic extract of black cohosh involves degradation of cytokeratin (CK) 18.
Hostanska K; Nisslein T; Freudenstein J; Reichling J; Saller R
Anticancer Res; 2005; 25(1A):139-47. PubMed ID: 15816531
[TBL] [Abstract][Full Text] [Related]
10. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
11. Protection of androgen-dependent human prostate cancer cells from oxidative stress-induced DNA damage by overexpression of clusterin and its modulation by androgen.
Miyake H; Hara I; Gleave ME; Eto H
Prostate; 2004 Dec; 61(4):318-23. PubMed ID: 15389725
[TBL] [Abstract][Full Text] [Related]
12. Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer.
Xie X; Zhao X; Liu Y; Zhang J; Matusik RJ; Slawin KM; Spencer DM
Cancer Res; 2001 Sep; 61(18):6795-804. PubMed ID: 11559553
[TBL] [Abstract][Full Text] [Related]
13. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms.
Tepper CG; Vinall RL; Wee CB; Xue L; Shi XB; Burich R; Mack PC; de Vere White RW
Prostate; 2007 Apr; 67(5):521-35. PubMed ID: 17252539
[TBL] [Abstract][Full Text] [Related]
14. Concentration-dependent effects of a selective estrogen receptor modulator raloxifene on proliferation and apoptosis in human uterine leiomyoma cells cultured in vitro.
Liu J; Matsuo H; Xu Q; Chen W; Wang J; Maruo T
Hum Reprod; 2007 May; 22(5):1253-9. PubMed ID: 17220163
[TBL] [Abstract][Full Text] [Related]
15. Par-4-dependent apoptosis by the dietary compound withaferin A in prostate cancer cells.
Srinivasan S; Ranga RS; Burikhanov R; Han SS; Chendil D
Cancer Res; 2007 Jan; 67(1):246-53. PubMed ID: 17185378
[TBL] [Abstract][Full Text] [Related]
16. Zanthoxyli Fructus induces growth arrest and apoptosis of LNCaP human prostate cancer cells in vitro and in vivo in association with blockade of the AKT and AR signal pathways.
Yang Y; Ikezoe T; Takeuchi T; Adachi Y; Ohtsuki Y; Koeffler HP; Taguchi H
Oncol Rep; 2006 Jun; 15(6):1581-90. PubMed ID: 16685399
[TBL] [Abstract][Full Text] [Related]
17. Differential regulation of IGFBP-3 by the androgen receptor in the lineage-related androgen-dependent LNCaP and androgen-independent C4-2 prostate cancer models.
Kojima S; Mulholland DJ; Ettinger S; Fazli L; Nelson CC; Gleave ME
Prostate; 2006 Jun; 66(9):971-86. PubMed ID: 16541420
[TBL] [Abstract][Full Text] [Related]
18. ERRgamma suppresses cell proliferation and tumor growth of androgen-sensitive and androgen-insensitive prostate cancer cells and its implication as a therapeutic target for prostate cancer.
Yu S; Wang X; Ng CF; Chen S; Chan FL
Cancer Res; 2007 May; 67(10):4904-14. PubMed ID: 17510420
[TBL] [Abstract][Full Text] [Related]
19. Phorbol ester-induced apoptosis is accompanied by NGFI-A and c-fos activation in androgen-sensitive prostate cancer cells.
Day ML; Zhao X; Wu S; Swanson PE; Humphrey PA
Cell Growth Differ; 1994 Jul; 5(7):735-41. PubMed ID: 7947388
[TBL] [Abstract][Full Text] [Related]
20. Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial.
Shazer RL; Jain A; Galkin AV; Cinman N; Nguyen KN; Natale RB; Gross M; Green L; Bender LI; Holden S; Kaplan L; Agus DB
BJU Int; 2006 Apr; 97(4):691-7. PubMed ID: 16536755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
